Research Group in Environmental Factors of Neurodegenerative Diseases, Health Research Institute Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Department of Neurology, Hospital Universitario de Torrejón, Madrid, Spain.
Front Immunol. 2022 Jun 14;13:904683. doi: 10.3389/fimmu.2022.904683. eCollection 2022.
MicroRNAs are small non-coding RNA that regulate gene expression at a post-transcriptional level affecting several cellular processes including inflammation, neurodegeneration and remyelination. Different patterns of miRNAs expression have been demonstrated in multiple sclerosis compared to controls, as well as in different courses of the disease. For these reason they have been postulated as promising biomarkers candidates in multiple sclerosis.
to correlate serum microRNAs profile expression with disability, cognitive functioning and brain volume in patients with remitting-relapsing multiple sclerosis.
cross-sectional study in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate. Disability was measured with Expanded Disability Status Scale (EDSS) and cognitive function was studied with Symbol Digit Modalities Test (SDMT). Brain volume was analyzed with automatic software NeuroQuant.
We found an association between miR.146a.5p (r:0.434, p=0.03) and miR.9.5p (r:0.516, p=0.028) with EDSS; and miR-146a.5p (r:-0.476, p=0.016) and miR-126.3p (r:-0.528, p=0.007) with SDMT. Regarding to the brain volume, miR.9.5p correlated with thalamus (r:-0.545, p=0.036); miR.200c.3p with pallidum (r:-0.68, p=0.002) and cerebellum (r:-0.472, p=0.048); miR-138.5p with amygdala (r:0.73, p=0.016) and pallidum (r:0.64, p=0.048); and miR-223.3p with caudate (r:0.46, p=0.04).
These data support the hypothesis of microRNA as potential biomarkers in this disease. More studies are needed to validate these results and to better understand the role of microRNAs in the pathogenesis, monitoring and therapeutic response of multiple sclerosis.
微小 RNA 是一种小的非编码 RNA，可在转录后水平调节基因表达，影响包括炎症、神经退行性变和髓鞘再生在内的多种细胞过程。与对照组相比，在多发性硬化症中已经证实了不同的 miRNA 表达模式，并且在疾病的不同病程中也有不同的表现。因此，它们被推测为多发性硬化症有希望的生物标志物候选物。
将血清微小 RNA 谱表达与缓解复发型多发性硬化症患者的残疾、认知功能和脑容量相关联。
对接受聚甘酯治疗的复发缓解型多发性硬化症患者进行横断面研究。采用扩展残疾状况量表（EDSS）测量残疾程度，采用符号数字模态测验（SDMT）研究认知功能。利用自动软件 NeuroQuant 分析脑容量。
我们发现 miR.146a.5p（r：0.434，p=0.03）和 miR.9.5p（r：0.516，p=0.028）与 EDSS 之间存在相关性；miR-146a.5p（r：-0.476，p=0.016）和 miR-126.3p（r：-0.528，p=0.007）与 SDMT 之间存在相关性。关于脑容量，miR.9.5p 与丘脑（r：-0.545，p=0.036）相关；miR.200c.3p 与苍白球（r：-0.68，p=0.002）和小脑（r：-0.472，p=0.048）相关；miR-138.5p 与杏仁核（r：0.73，p=0.016）和苍白球（r：0.64，p=0.048）相关；miR-223.3p 与尾状核（r：0.46，p=0.04）相关。
这些数据支持微小 RNA 作为该疾病潜在生物标志物的假说。需要进一步研究来验证这些结果，并更好地理解微小 RNA 在多发性硬化症的发病机制、监测和治疗反应中的作用。
